Gut microbiota-derived short-chain fatty acids (SCFAs): immunomodulatory effects and therapeutic potential in infections
Clinical Microbiology Reviews · 10.09.2026 · 39 (3)
DOI: 10.1128/cmr.00368-25 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Microbiology Reviews, erschienen am 10.09.2026. Verfasst von Junxiu Yu und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Trauma-Emergency & Critical Care Medicine, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Fatty Acids, Volatile, Gastrointestinal Microbiome, Immunologic Factors. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 185 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Science and Technology Innovation Plan of the Shanghai Science and Technology Commission, the Minhang District Major Medical Discipline Construction Project.
Abstract (Originalsprache)
The human gut microbiotas constitute a complex microecosystem essential for host homeostasis. Among its metabolites, short-chain fatty acids (SCFAs) act as key signaling molecules linking microbial activity to host immunity and barrier function. Based on existing literature, we conducted a comprehensive analysis of the interaction between SCFAs and 11 key gut pathogens. These pathogens include bacteria (i.e., Staphylococcus aureus , Clostridioides difficile, Salmonella spp. , Campylobacter jejuni, Klebsiella pneumoniae, Vibrio cholerae ), fungi (i.e., Candida albicans ), and viruses (i.e., SARS-CoV-2, influenza virus, respiratory syncytial virus, rotavirus). In terms of antibacterial effects, SCFAs exhibit antibacterial activity against most gut microorganisms, but they support the colonization of a few species (i.e., Campylobacter jejuni ). Given the complex interactions between SCFAs and the gut microbiota, as well as their regulatory roles in infection, further investigation of the microbiota-SCFA axis is essential for developing effective strategies to prevent and treat infectious diseases. This review systematically summarizes the mechanism and clinical evidence of SCFAs in microbial infections to provide novel ideas for infectious disease management.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Trauma-Emergency & Critical Care Medicine, Shanghai Fifth People's Hospital, Fudan University, Shanghai, China.
ORCID-Profile: Junxiu Yu, Wenweiran Li, Yajie Xu, Jianguo Tang
Förderung
- the National Natural Science Foundation of China
- the Science and Technology Innovation Plan of the Shanghai Science and Technology Commission
- the Minhang District Major Medical Discipline Construction Project
Zitieren
APA
Yu, J., Li, W., Xu, Y., & Tang, J. (2026). Gut microbiota-derived short-chain fatty acids (SCFAs): immunomodulatory effects and therapeutic potential in infections. Clinical Microbiology Reviews, 39(3). https://doi.org/10.1128/cmr.00368-25
Vancouver
Yu J, Li W, Xu Y, Tang J. Gut microbiota-derived short-chain fatty acids (SCFAs): immunomodulatory effects and therapeutic potential in infections. Clinical Microbiology Reviews. 2026;39(3). doi:10.1128/cmr.00368-25
BibTeX
@article{Yu2026,
author = {Yu, Junxiu and Li, Wenweiran and Xu, Yajie and Tang, Jianguo},
title = {Gut microbiota-derived short-chain fatty acids (SCFAs): immunomodulatory effects and therapeutic potential in infections},
journal = {Clinical Microbiology Reviews},
year = {2026},
volume = {39},
number = {3},
doi = {10.1128/cmr.00368-25}
}
EUVIMED